KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Share-based Compensation (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Share-based Compensation data on record, last reported at $13.5 million in Q4 2025.

  • For Q4 2025, Share-based Compensation rose 10.05% year-over-year to $13.5 million; the TTM value through Dec 2025 reached $57.5 million, up 12.37%, while the annual FY2025 figure was $57.5 million, 12.37% up from the prior year.
  • Share-based Compensation reached $13.5 million in Q4 2025 per PCRX's latest filing, down from $14.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $15.5 million in Q2 2025 and bottomed at $10.1 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $12.3 million, with a median of $12.5 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: dropped 5.1% in 2023, then increased 23.54% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $10.9 million in 2021, then rose by 16.4% to $12.7 million in 2022, then decreased by 2.03% to $12.4 million in 2023, then dropped by 1.24% to $12.3 million in 2024, then rose by 10.05% to $13.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $13.5 million in Q4 2025, $14.0 million in Q3 2025, and $15.5 million in Q2 2025.